The PDX ROS1-fusion tumor cell line, LUAD-0006, is resistant to all
4.9 (276) · $ 4.50 · In stock
PDF) NRG1 and NRG2 fusion positive solid tumor malignancies: a
Igor Odintsov's research works Brigham and Women's Hospital
Establishment and characterization of a cell line and patient
Patient-derived xenograft culture-transplant system for investigation
Protein tyrosine kinase inhibitor resistance in malignant tumors
Intraductal xenografts show lobular carcinoma cells rely on their
A highly multiplexed quantitative phosphosite assay for biology
Gregory J. Riely's research works
NTRK and NRG1 gene fusions in advanced non-small cell lung cancer
Inna Khodos's research works Memorial Sloan Kettering Cancer
Targeted therapy for rare lung cancers: Status, challenges, and
Frontiers ROS1 Fusion Mediates Immunogenicity by Upregulation of
Monika DAVARE, Professor (Associate), PhD
